enGene (NASDAQ:ENGN) Now Covered by Analysts at Wells Fargo & Company

Equities research analysts at Wells Fargo & Company started coverage on shares of enGene (NASDAQ:ENGN - Get Free Report) in a report released on Monday, Marketbeat.com reports. The brokerage set an "overweight" rating and a $30.00 price target on the stock. Wells Fargo & Company's price objective indicates a potential upside of 102.70% from the stock's previous close.

A number of other equities analysts have also weighed in on ENGN. SVB Leerink initiated coverage on enGene in a research note on Tuesday, February 20th. They issued an "outperform" rating and a $31.00 target price on the stock. Morgan Stanley started coverage on enGene in a report on Friday, March 8th. They issued an "overweight" rating and a $40.00 price objective for the company. Guggenheim began coverage on enGene in a report on Monday, April 15th. They issued a "buy" rating and a $34.00 price objective for the company. UBS Group began coverage on enGene in a report on Thursday, March 28th. They set a "buy" rating and a $37.00 target price for the company. Finally, Leerink Partnrs restated an "outperform" rating on shares of enGene in a report on Tuesday, February 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $34.40.

enGene Stock Down 0.3 %

NASDAQ ENGN traded down $0.05 during trading on Monday, reaching $14.80. The company's stock had a trading volume of 65,845 shares, compared to its average volume of 43,481. The stock has a fifty day moving average of $15.97. enGene has a one year low of $6.69 and a one year high of $43.00.

Insiders Place Their Bets

In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total value of $717,810.00. Following the completion of the sale, the insider now owns 3,036,153 shares in the company, valued at approximately $45,542,295. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Vivo Capital LLC bought a new position in enGene during the 4th quarter valued at approximately $6,264,000. Omega Fund Management LLC bought a new position in enGene during the 4th quarter valued at approximately $10,441,000. BVF Inc. IL bought a new position in enGene during the 4th quarter valued at approximately $20,777,000. Finally, Fcpm Iii Services B.V. bought a new position in enGene during the 4th quarter valued at approximately $80,097,000. Institutional investors own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.